$STE

Carestio Daniel A sold $947K of STE

Carestio Daniel A (President and CEO) sold 4,428 shares of STERIS plc (STE) at an average of $213.82 ($212.00–$214.64, $0.95M total) across 2 trades over 2026-06-04 to 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Carestio Daniel A
Published Jun 8, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STE
Neutral
medium confidence
Mentioned
$STE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The only new information is the CEO’s open-market sale details (size, price range, and 10b5-1 pre-arrangement).

02

Market read

Traders may monitor for follow-on scheduled insider activity, but the 10b5-1 designation limits interpretive value for fundamentals.

03

What to watch

The article doesn’t state whether the CEO’s remaining holdings are subject to other scheduled sales, nor does it provide context on option exercises/compensation—those could offset the net selling narrative.

Relevance 4/10Novelty 5/10Timing: Filed June 8, covering sales executed June 4–5

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for STERIS plc (STE).

Company-level read

Ticker impact

$STENeutralMedium confidence
Context

SEC Form 4 shows STE CEO sold 4,428 shares in open-market transactions totaling about $946.8K under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a primary-source insider transaction, but it is explicitly tied to a pre-arranged 10b5-1 plan and provides no new operating/financial information.

Market effects

Minimal—this is company-specific insider activity with no stated sector-wide signal.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with valuation or liquidity needs; traders may treat it as a mild overhang if price is extended.

Key entities

  • STERIS plc

    Company whose CEO insider sale is disclosed via SEC Form 4.

  • Carestio Daniel A

    President and CEO who sold shares under a pre-arranged 10b5-1 plan.

Related articles

$STEMed

STERIS plc (STE): Results of Operations and Financial Condition

STERIS plc (STE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ste6302026ex991.htm EX-99.1 Document Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 First Quarter • Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% • Fiscal 2027 first quarter as reported diluted EPS incre

$STEMedAI 8/10

Are Wall Street Analysts Predicting STERIS Stock Will Climb or Sink?

STERIS plc (STE) has lagged the market, falling 11.2% over the past year versus a 27.9% S&P 500 gain, and is down 14.6% in 2026 YTD. After Q4 results on May 11 (revenue $1.6B, +7.3% YoY; adjusted EPS $2.83, +3.3%), analysts expect FY2027 EPS of $11.18 (+9.9%). Consensus is “Moderate Buy” (5 “Strong Buy,” 3 “Hold”); KeyBanc cut its target to $269.